A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450)

PHASE3CompletedINTERVENTIONAL
Enrollment

983

Participants

Timeline

Start Date

September 19, 2011

Primary Completion Date

September 18, 2013

Study Completion Date

September 18, 2013

Conditions
Contraception
Interventions
DRUG

ENG 120 µg + EE 15 µg intravaginal ring

13 cycles of ENG-EE (NuvaRing) vaginal ring use. Each cycle 28 days, with a 21-day active treatment period followed by 7-day ring-free period. One ring per cycle, each ring containing 11.7 mg ENG and 2.7 mg EE, and releasing on average 120 mcg/day of ENG and 15 mcg/day of EE.

DRUG

DRSP 3 mg + EE 30 µg

13 cycles of DRSP-EE tablet use. Each cycle 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received total of 21 tablets per cycle, each tablet contained 3 mg DRSP and 30 μg EE.

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT01277211 - A Study to Evaluate the Effectiveness of NuvaRing® to Prevent Pregnancies in Chinese Women (P06450) | Biotech Hunter | Biotech Hunter